nach oben

Erschienen in:

19.04.2017 | Original Article

Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy

verfasst von: Hideya Yamazaki, MD, Yusuke Demizu, MD, Tomoaki Okimoto, MD, Mikio Ogita, MD, Kengo Himei, MD, Satoaki Nakamura, MD, Gen Suzuki, MD, Ken Yoshida, MD, Tadayuki Kotsuma, MD, Yasuo Yoshioka, MD, Ryoongjin Oh, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To examine the outcomes of reirradiation for recurrent head and neck cancers using different modalities.

Methods

This retrospective study included 26 patients who received charged particle radiotherapy (CP) and 150 who received photon radiotherapy (117 CyberKnife radiotherapy [CK] and 36 intensity-modulated radiotherapy [IMRT]). Inverse probability of treatment weighting (IPTW) involving propensity scores was used to reduce background selection bias.

Results

Higher prescribed doses were used in CP than photon radiotherapy. The 1‑year overall survival (OS) rates were 67.9% for CP and 54.1% for photon radiotherapy (p = 0.15; 55% for CK and 51% for IMRT). In multivariate Cox regression, the significant prognostic factors for better survival were nasopharyngeal cancer, higher prescribed dose, and lower tumor volume. IPTW showed a statistically significant difference between CP and photon radiotherapy (p = 0.04). The local control rates for patients treated with CP and photon radiotherapy at 1 year were 66.9% (range 46.3–87.5%) and 67.1% (range 58.3–75.9%), respectively. A total of 48 patients (27%) experienced toxicity grade ≥3 (24% in the photon radiotherapy group and 46% in the CP group), including 17 patients with grade 5 toxicity. Multivariate analysis revealed that younger age and a larger planning target volume (PTV) were significant risk factors for grade 3 or worse toxicity.

Conclusion

CP provided superior survival outcome compared to photon radiotherapy. Tumor volume, primary site (nasopharyngeal), and prescribed dose were identified as survival factors. Younger patients with a larger PTV experienced toxicity grade ≥3.

Mazeron R, Tao Y, Lusinchi A, Bourhis J (2009) Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncol 45:402–408CrossRefPubMed

Vokes EE, Weichselbaum RR, Lippman SM et al (1993) Head and neck cancer. N Eng J Med 328:184–194CrossRef

Temam S, Pape E, Janot F et al (2005) Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 62:1078–1083CrossRefPubMed

Wong SJ, Machtay M, Li Y et al (2006) Locally recurrent, previously irradiated head and neck cancer: concurrent reirradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 24:2653–2658CrossRefPubMed

Hoebers F, Heemsbergen W, Moor S et al (2011) Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 81:e111–e118CrossRefPubMed

Morimoto K, Demizu Y, Hashimoto N et al (2014) Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skull base invasion. Jpn J Clin Oncol 44:428–434CrossRefPubMed

Miyawaki D, Murakami M, Demizu Y et al (2009) Brain injury after proton therapy or carbon ion therapy for head-and-neck cancer and skull base tumors. Int J Radiat Oncol Biol Phys 75:378–384CrossRefPubMed

Demizu Y, Fujii O, Terashima K et al (2014) Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. Strahlenther Onkol 190:186–191CrossRefPubMed

Takagi M, Demizu Y, Hashimoto N et al (2014) Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 113:364–370CrossRefPubMed

10.

Yamazaki H, Demizu Y, Okimoto T et al (2016) Comparison of re-irradiation outcomes for charged particle radiotherapy and robotic stereotactic radiotherapy using cyberknife for recurrent head and neck cancers: a multi-institutional matched-cohort analysis. Anticancer Res 10:5507–5514

11.

Yamazaki H, Ogita M, Himei K et al (2016) Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer. J Radiat Res 57:288–293CrossRefPubMedPubMedCentral

12.

Doi H, Oh RJ, Miura H, Masai N, Shiomi H, Inoue T (2016) Outcomes and toxicity of radiotherapy for refractory bone and soft tissue sarcomas. Mol Clin Oncol 4:83–88PubMed

13.

Kagawa K, Murakami M, Hishikawa Y et al (2002) Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. Int J Radiat Oncol Biol Phys 54:928–938CrossRefPubMed

14.

R-project home page: https://www.r-project.org/. Accessed Aug 8, 2016

15.

Ohizumi Y, Tamai Y, Imamiya S et al (2002) Prognostic factors ofreirradiation for recurrent head and neck cancer. Am J Clin Oncol 25:408–413CrossRefPubMed

16.

Spencer SA, Harris J, Wheeler RH et al (2008) Final report of RTOG 9610, a multiinstitutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30:281–288CrossRefPubMed

17.

Margalit DN, Rawal B, Catalano PJ et al (2016) Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol 61:19–26CrossRefPubMed

18.

Kodani N, Yamazaki H, Tsubokura T et al (2011) Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res 52:24–31CrossRefPubMed

19.

Yamazaki H, Ogita M, Kodani N et al (2015) Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: a multi-institutional matched-cohort analysis. Radiother Oncol 115:67–71CrossRefPubMed

20.

Yamazaki H, Ogita M, Himei K et al (2015) Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: a multi-institutional matched-cohort analysis. Radiother Oncol 115:67–71CrossRefPubMed

21.

Lartigau EF, Tresch E, Thariat J et al (2013) A. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol 109:281–285CrossRefPubMed

22.

Yazici G, Sanlı TY, Cengiz M et al (2013) A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat Oncol 8:242CrossRefPubMedPubMedCentral

23.

Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, Gunn GB, Fuller CD, Beadle B, Frank SJ, William WN Jr et al (2016) Reirradiation of head and neck cancers with intensity modulated radiation therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys 95:1117–1131CrossRefPubMed

24.

Phan J, Sio TT, Nguyen TP et al (2016) Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys 96:30–41CrossRefPubMed

25.

Vargo JA, Ferris RL, Ohr J et al (2015) A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91:480–488CrossRefPubMed

Titel: Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy
verfasst von: Hideya Yamazaki, MD
Yusuke Demizu, MD
Tomoaki Okimoto, MD
Mikio Ogita, MD
Kengo Himei, MD
Satoaki Nakamura, MD
Gen Suzuki, MD
Ken Yoshida, MD
Tadayuki Kotsuma, MD
Yasuo Yoshioka, MD
Ryoongjin Oh, MD
Publikationsdatum: 19.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1129-6

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer

Patient-reported symptoms during radiotherapy

Konsolidierende Lokaltherapie verbessert progressionsfreies Überleben von Patienten mit oligometastasiertem NSCLC

General health status of long-term cervical cancer survivors after radiotherapy

Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease

Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie